Geneuro SA - Asset Resilience Ratio
Geneuro SA (GNRO) has an Asset Resilience Ratio of 28.72% as of December 2023. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read total liabilities of Geneuro SA for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2012–2023)
This chart shows how Geneuro SA's Asset Resilience Ratio has changed over time. See GNRO cash flow after capex ratio to measure how efficiently the company converts operating cash flow to free cash.
Liquid Assets Composition Over Time
This chart breaks down Geneuro SA's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see Geneuro SA balance sheet assets.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €1.83 Million | 28.72% |
| Short-term Investments | €0.00 | 0% |
| Total Liquid Assets | €1.83 Million | 28.72% |
Asset Resilience Insights
- Very High Liquidity: Geneuro SA maintains exceptional liquid asset reserves at 28.72% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company primarily holds liquidity in cash and equivalents rather than short-term investments.
Geneuro SA Industry Peers by Asset Resilience Ratio
Compare Geneuro SA's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 0.00% |
|
argenx NV ADR
NASDAQ:ARGX |
Biotechnology | 15.95% |
|
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL |
Biotechnology | 62.31% |
|
Halozyme Therapeutics Inc
NASDAQ:HALO |
Biotechnology | 12.71% |
|
Ligand Pharmaceuticals Incorporated
NASDAQ:LGND |
Biotechnology | 16.06% |
|
ABCELLERA BIOLOGICS
F:8QQ |
Biotechnology | 32.12% |
|
Gempharmatech Co. Ltd. A
SHG:688046 |
Biotechnology | 23.95% |
|
Sinopep-Allsino Biopharmaceutical Co. Ltd. A
SHG:688076 |
Biotechnology | 0.91% |
Annual Asset Resilience Ratio for Geneuro SA (2012–2023)
The table below shows the annual Asset Resilience Ratio data for Geneuro SA.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2023-12-31 | 28.72% | €1.83 Million ≈ $2.14 Million |
€6.36 Million ≈ $7.44 Million |
-20.25pp |
| 2022-12-31 | 48.98% | €5.59 Million ≈ $6.54 Million |
€11.42 Million ≈ $13.35 Million |
+4.86pp |
| 2021-12-31 | 44.11% | €5.48 Million ≈ $6.41 Million |
€12.42 Million ≈ $14.52 Million |
-21.46pp |
| 2020-12-31 | 65.57% | €6.84 Million ≈ $8.00 Million |
€10.44 Million ≈ $12.20 Million |
+1.80pp |
| 2019-12-31 | 63.77% | €5.93 Million ≈ $6.93 Million |
€9.30 Million ≈ $10.87 Million |
+14.08pp |
| 2014-12-31 | 49.69% | €4.50 Million ≈ $5.26 Million |
€9.06 Million ≈ $10.59 Million |
+1.50pp |
| 2013-12-31 | 48.19% | €2.02 Million ≈ $2.36 Million |
€4.20 Million ≈ $4.91 Million |
+45.28pp |
| 2012-12-31 | 2.92% | €150.00K ≈ $175.37K |
€5.14 Million ≈ $6.01 Million |
-- |
About Geneuro SA
GeNeuro SA, a clinical-stage biopharmaceutical company, develops drugs for the treatment of neurodegenerative and autoimmune diseases. The company's lead therapeutic candidate is temelimab, a monoclonal antibody that neutralizes a pathogenic protein of the HERV-W family that has completed a Phase II clinical trials. It is also developing GNC-501 for post-COVID on patients with persistent neuropsy… Read more